Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Inhibiting HIF2A for asthma

BC Staff
January 28, 2025 12:49 AM UTC

Inhibiting the transcription factor HIF2A could help treat asthma by preventing the polarization of stem-like Th2 cells into pathogenic Th2 cells in the lungs, thus decreasing airway inflammation.

In bioinformatic analyses of public patient data sets, HIF2A was highly expressed in pathogenic Th2 cells in lung and nasal polyp samples, respectively, from asthma patients and patients with chronic rhinosinusitis with nasal polyp who also had ongoing or historical asthma. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Sichuan University

Third Military Medical University